Alan H. Bryce

51.3k total citations
167 papers, 2.5k citations indexed

About

Alan H. Bryce is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Alan H. Bryce has authored 167 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 105 papers in Pulmonary and Respiratory Medicine, 81 papers in Oncology and 51 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Alan H. Bryce's work include Prostate Cancer Treatment and Research (89 papers), Radiopharmaceutical Chemistry and Applications (42 papers) and Cancer Genomics and Diagnostics (25 papers). Alan H. Bryce is often cited by papers focused on Prostate Cancer Treatment and Research (89 papers), Radiopharmaceutical Chemistry and Applications (42 papers) and Cancer Genomics and Diagnostics (25 papers). Alan H. Bryce collaborates with scholars based in United States, United Kingdom and Pakistan. Alan H. Bryce's co-authors include Emmanuel S. Antonarakis, Thai H. Ho, Christopher Ryan, Andrea McNatty, Aleksandar Sekulić, Rafaël Fonseca, Robert A. Kyle, Angela Dispenzieri, Nicholas J. Vogelzang and Mitesh J. Borad and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Alan H. Bryce

156 papers receiving 2.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alan H. Bryce United States	26	1.3k	1.0k	642	545	301	167	2.5k
Ishmael Jaiyesimi United States	21	784 0.6×	1.3k 1.2×	632 1.0×	537 1.0×	302 1.0×	119	3.1k
Ellis Levine United States	26	946 0.7×	1.1k 1.1×	641 1.0×	664 1.2×	260 0.9×	92	2.8k
Fariba Navid United States	31	1.3k 1.0×	896 0.9×	686 1.1×	298 0.5×	218 0.7×	104	2.8k
Fabio A.B. Schutz United States	21	1.2k 0.9×	1.4k 1.4×	638 1.0×	281 0.5×	203 0.7×	46	2.9k
Yukinori Sakao Japan	30	2.2k 1.8×	1.2k 1.1×	483 0.8×	359 0.7×	371 1.2×	180	3.0k
James T. Symanowski United States	28	3.1k 2.5×	1.4k 1.3×	680 1.1×	451 0.8×	484 1.6×	172	4.8k
Yuanyuan Zhao China	29	1.1k 0.9×	1.9k 1.8×	558 0.9×	533 1.0×	209 0.7×	162	3.0k
Sun Min Lim South Korea	27	1.6k 1.3×	1.5k 1.4×	900 1.4×	521 1.0×	156 0.5×	132	2.8k
Christian Rothermundt Switzerland	25	971 0.8×	1.0k 1.0×	755 1.2×	371 0.7×	96 0.3×	79	2.3k
Lin Gu United States	27	1.7k 1.3×	1.0k 1.0×	436 0.7×	268 0.5×	244 0.8×	105	2.8k

Countries citing papers authored by Alan H. Bryce

Since Specialization

Citations

This map shows the geographic impact of Alan H. Bryce's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan H. Bryce with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan H. Bryce more than expected).

Fields of papers citing papers by Alan H. Bryce

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan H. Bryce. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan H. Bryce. The network helps show where Alan H. Bryce may publish in the future.

Co-authorship network of co-authors of Alan H. Bryce

This figure shows the co-authorship network connecting the top 25 collaborators of Alan H. Bryce. A scholar is included among the top collaborators of Alan H. Bryce based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alan H. Bryce. Alan H. Bryce is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chen, Ronald C., Viraj A. Master, Lanyu Mi, et al.. (2025). Thromboembolic Events in Castration‐Resistant Prostate Cancer Patients With and Without Cardiovascular Comorbidities Receiving Oral Androgen Receptor Pathway Inhibitors. The Prostate. 85(10). 954–965.

Naqvi, Syed Arsalan Ahmed, Jack R. Andrews, Alan H. Bryce, et al.. (2025). Automated risk stratification in localized prostate cancer using an AI-assisted framework.. Journal of Clinical Oncology. 43(5_suppl). 341–341.

Bryce, Alan H., Ray McDermott, Josep M. Piulats, et al.. (2025). Rucaparib vs docetaxel (DTX) or second-generation androgen pathway inhibitor (ARPI) therapy for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 final overall survival (OS) and safety.. Journal of Clinical Oncology. 43(5_suppl). 155–155. 3 indexed citations

Ensign, Shannon P. Fortin, Akanksha Sharma, Richard Butterfield, et al.. (2023). Clinical Outcomes of Stereotactic Radiosurgery-Related Radiation Necrosis in Patients with Intracranial Metastasis from Melanoma. Clinical Medicine Insights Oncology. 17. 1373282838–1373282838. 4 indexed citations

Ahmed, Mohamed E., Ahmed Mahmoud, Raevti Bole, et al.. (2023). Early PSA decline after starting second-generation hormone therapy in the post-docetaxel setting predicts cancer-specific survival in metastatic castrate-resistant prostate cancer. Prostate Cancer and Prostatic Diseases. 27(2). 334–338. 1 indexed citations

Ahmed, Mohamed E., Raevti Bole, Jack R. Andrews, et al.. (2023). High-volume mCRPC is associated with decreased cancer specific survival in patients on second-generation hormone therapy in the post docetaxel setting.. Journal of Clinical Oncology. 41(6_suppl). 192–192. 1 indexed citations

Riaz, Irbaz Bin, et al.. (2023). Source of funding and enrollment disparity in prostate cancer (PCa) clinical trials.. Journal of Clinical Oncology. 41(6_suppl). 40–40. 1 indexed citations

Sicotte, Hugues, Krishna R. Kalari, Sisi Qin, et al.. (2022). Molecular Profile Changes in Patients with Castrate-Resistant Prostate Cancer Pre- and Post-Abiraterone/Prednisone Treatment. Molecular Cancer Research. 20(12). 1739–1750. 9 indexed citations

Labadie, Brian, David Morris, Alan H. Bryce, et al.. (2022). Guidelines for Management of Treatment-Emergent Adverse Events During Rucaparib Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer. SHILAP Revista de lepidopterología. 4 indexed citations

10.

Karp, Daniel D., D. Ross Camidge, J. Infante, et al.. (2022). Phase I study of PT-112, a novel pyrophosphate-platinum immunogenic cell death inducer, in advanced solid tumours. EClinicalMedicine. 49. 101430–101430. 25 indexed citations

11.

Chowdhury, S., Akash Patnaik, David Campbell, et al.. (2020). 659P Rucaparib population pharmacokinetics (PPK) and exposure-response (ER) analyses in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in TRITON2. Annals of Oncology. 31. S533–S534. 2 indexed citations

12.

Karp, Daniel D., Roxana Dronca, D. Ross Camidge, et al.. (2020). 1026MO Phase Ib dose escalation study of novel immunogenic cell death (ICD) inducer PT-112 plus PD-L1 inhibitor avelumab in solid tumours. Annals of Oncology. 31. S708–S708. 5 indexed citations

13.

Zarei, Shabnam, Jesse S. Voss, Alan H. Bryce, et al.. (2019). Mutational Profile in Vulvar, Vaginal, and Urethral Melanomas: Review of 37 Cases With Focus on Primary Tumor Site. International Journal of Gynecological Pathology. 39(6). 587–594. 21 indexed citations

14.

Bryce, Alan H., Joshi J. Alumkal, Andrew J. Armstrong, et al.. (2017). Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL. Prostate Cancer and Prostatic Diseases. 20(2). 221–227. 71 indexed citations

15.

Conroy, Michael, Mitesh J. Borad, & Alan H. Bryce. (2017). Hypoxia-Activated Alkylating Agents in BRCA1-Mutant Ovarian Serous Carcinoma. Cureus. 9(7). e1517–e1517. 5 indexed citations

16.

Wong, William W., Homan Mohammadi, T.B. Daniels, et al.. (2016). Predictors for Survival After Radium-223 Treatment for Castration-Resistant Metastatic Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics. 96(2). E255–E255. 1 indexed citations

17.

Hart, Steven N., Marissa S. Ellingson, Peter T. Vedell, et al.. (2016). Determining the frequency of pathogenic germline variants from exome sequencing in patients with castrate-resistant prostate cancer. BMJ Open. 6(4). e010332–e010332. 28 indexed citations

18.

Joseph, Richard W., Sherri Z. Millis, Estrella M. Carballido, et al.. (2015). PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation. Cancer Immunology Research. 3(12). 1303–1307. 131 indexed citations

19.

Dispenzieri, Angela, Martha Q. Lacy, Suzanne R. Hayman, et al.. (2008). Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome. European Journal Of Haematology. 80(5). 397–406. 78 indexed citations

20.

Lindeman, Melissa, Kirsten Black, R. B. Smith, et al.. (2003). Changing Practice in Residential Aged Care Using Participatory Methods. Education for Health. 16(1). 22–31. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact